Employee at a location where AstraZeneca’s Covid-19 vaccine candidate is being tested with Oxford University in São Paulo
The vaccine developed by the University of Oxford, in collaboration with the company AstraZeneca, would generate a robust response in immunity among the elderly. These were the results obtained in clinical tests and will soon be published in scientific journals.
The information was revealed this Monday morning by the Financial Times. The column confirmed that the World Health Organization had already received information in the same direction, which opened the possibility even for the agency to have publicly declared that it was “optimistic” about the performance of clinical tests.
Experts, however, warn that the positive result should be celebrated with caution. The robust response does not necessarily mean that the vaccine will be safe or that it will in fact generate adequate immunity. The Oxford vaccine is part of an agreement with the federal government in Brazil, in a project that involves Fiocruz.